



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicant:** Noujaim  
**Serial No.:** 09/779,439  
**Filed:** February 8, 2001  
**Entitled:** METHOD FOR DIAGNOSING EFFICACY OF  
XENOTYPIC ANTIBODY THERAPY  
**Examiner:** L. Helms  
**Group Art Unit:** 1642  
**Attorney Docket:** ALT-006US1 (1009/007)

Assistant Commissioner for Patents  
Washington, DC 20231

# 10  
JW  
7/13/02  
**RECEIVED**

JUL 08 2002

TECH CENTER 1600/2900

COPY OF PAPERS  
ORIGINALLY FILED

**RESPONSE TO RESTRICTION REQUIREMENT**

Dear Sir:

Claims 1-25 are pending in this application, and stand subject to a Restriction Requirement mailed April 25, 2002. A Petition for One-Month Extension of time up to and including June 25, 2002 along with the requisite fee is enclosed.

Applicants elect Claims 22-25, drawn to a method of diagnosing the efficacy of antibody mediated immunotherapy by measuring the level of a T cell response, classified in class 435, subclass 7.1.

If there are any questions, please contact the undersigned at the telephone number indicated below.

Date: 6/21/02

Respectfully submitted,

W. A. Keown

Wayne A. Keown, Ph.D.  
Reg. No. 33,923  
500 West Cummings Park  
Suite 2900  
Woburn, MA 01801  
781-938-1805 (Telephone)  
781-938-4777 (Facsimile)